BACKGROUND:

CXCR4–CXCL12 signaling anchors malignant B cells within protective marrow and nodal niches, driving immune evasion and drug resistance. Activating CXCR4 mutations (e.g., WHIM-like truncations) are present in ~30–40% of Waldenström macroglobulinemia (WM) and are associated with inferior responses to BTK inhibition; CXCR4 overexpression similarly portends adverse biology in diffuse large B-cell lymphoma (DLBCL). WHIM syndrome provides a human proof-of-concept that CXCR4 hyperactivation is disease-defining and reversible.

METHODS:

We performed a translational synthesis integrating (1) CRISPR–Cas9 editing studies of CXCR4 in WHIM hematopoietic stem/progenitor cells (HSPCs), (2) preclinical WM/DLBCL models of CXCR4 dependence, and (3) public datasets (TCGA-DLBC, CCLE) assessing CXCR4 expression and outcomes. Conceptual intervention modeling evaluated combinations of CXCR4 disruption with BTK inhibitors and CD19-directed CAR T cells.

RESULTS:

CRISPR-mediated disruption of mutant CXCR4 in WHIM HSPCs yields selective clonal advantage and durable multilineage reconstitution, establishing CXCR4 as a tractable driver. In TCGA-DLBC, high CXCR4 expression (upper quartile) correlates with inferior survival (median ~32 vs 68 months; HR ~1.5–1.7). CCLE demonstrates consistent CXCR4 expression across DLBCL lines, supporting lineage dependency. In WM, CXCR4 mutations correlate with delayed/attenuated responses to BTK inhibitors and increased marrow retention.

Mechanistically, CXCR4 activation enhances homing/retention within CXCL12 niches, limiting cytotoxic T-cell and CAR T-cell trafficking. Disruption of CXCR4 signaling is predicted to mobilize tumor cells, reduce stromal protection, and augment immune-mediated clearance. Preclinical data support synergy between CXCR4 blockade and immunotherapy, including improved CAR T-cell infiltration and function.

DISCUSSION:
WHIM gene correction demonstrates that editing a trafficking pathway can reverse disease biology upstream of survival signaling. Translating this paradigm to oncology suggests two strategies: (1) genetic or pharmacologic CXCR4 disruption to dislodge tumor cells from protective niches, and (2) combination with CAR T or BTK inhibition to exploit increased tumor accessibility.

CONCLUSION:
CXCR4 is a microenvironmental dependency in WM and DLBCL. Lessons from WHIM support CRISPR-enabled targeting of CXCR4 as a strategy to overcome resistance.